日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Integrated clinical and proteomic-based model for diagnostic and prognostic prediction in pRCC

基于临床和蛋白质组学的整合模型用于乳头状肾细胞癌的诊断和预后预测

Xu, Zeya; Zhang, Linhui; Lyu, Jiacheng; Cai, Maoping; Ji, Tao; Bai, Lin; Li, Liqing; Zhu, Yao; Xu, Huashan; Tan, Subei; Gan, Hualei; Ni, Shujuan; Xu, Wenhao; Tian, Xi; Anwaier, Aihetaimujiang; Liu, Beiyan; Hou, Qinqin; Shi, Guohai; Zhang, Hailiang; Zhao, Jianyuan; Ye, Dingwei; Qu, Yuanyuan; Ding, Chen

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study

新辅助氟哌啶醇联合阿比特龙治疗局限性高危前列腺癌(FAST-PC):一项单臂 II 期研究

Zhang, Tingwei; Wang, Beihe; Wei, Yu; Gan, Hualei; Fang, Bangwei; Li, Xiaomeng; Wu, Junlong; Bian, Xiaojie; Wang, Jianfei; Freedland, Stephen J; Huang, Shenglin; Ye, Dingwei; Zhu, Yao

Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget's disease

针对HER2低表达或高表达的晚期乳房外Paget病的抗体药物偶联物(disitamab vedotin)疗法

Zhang, Sheng; Zhou, Juan; Zhao, Xiaoying; Gan, Hualei; Peng, Wenxia; Li, Wenfeng; Sun, Mingjuan; Hu, Jiong; Yan, Wangjun

The value of MRI-based radiomics and clinicoradiological data for the detection of forkhead box protein A1 gene mutated prostate cancer

基于MRI的放射组学和临床放射学数据在检测叉头框蛋白A1基因突变型前列腺癌中的价值

Deng, Lin; Chen, Ruchuan; Zhou, Bingni; Hu, Guoqing; Gan, Hualei; Zhang, Ling; Zhou, Liangping; Liu, Kefu; Liu, Xiaohang

Biparametric magnetic resonance imaging-based radiomics model can improve the detection of dense and sparse prostate cancers

基于双参数磁共振成像的放射组学模型可以提高致密型和稀疏型前列腺癌的检出率。

Zhou, Bingni; Wang, Ting; Chen, Zhangzhe; Lv, Hong; Gan, Hualei; Li, Rong; Zhou, Liangping; Liu, Xiaohang; Gu, Yajia

Proteogenomic Analysis Identifies Clinically Relevant Subgroups of Collecting Duct Carcinoma.

蛋白质基因组学分析鉴定出具有临床意义的集合管癌亚组

Qu Yuanyuan, Pei Xiaoru, Feng Jinwen, Yan Xin, Zhang Linhui, Wang Jun, Yao Xin, Bian Jiasheng, Gan Yu, Gan Hualei, Jiang Xuewen, Yang Ping, Cai Maoping, Li Liqing, Wu Xinqiang, Jing Weiwei, Zhang Chao, Zhao Jianyuan, Zhang Hailiang, Shi Guohai, Zhou Xiang, Ye Dingwei, Ding Chen

Comprehensive Collection of Whole-Slide Images and Genomic Profiles for Patients with Bladder Cancer

膀胱癌患者全切片图像和基因组图谱的综合收集

Xu, Pei-Hang; Li, Tianqi; Qu, Fengmei; Tian, Mingkang; Wang, Jun; Gan, Hualei; Ye, Dingwei; Ren, Fei; Shen, Yijun

Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study

预测去势抵抗性前列腺癌中PSMA阴性但FDG阳性病灶的列线图:一项多中心队列研究

Pan, Jian; Zhang, Tingwei; Chen, Shouzhen; Bu, Ting; Zhao, Jinou; Ni, Xudong; Shi, Benkang; Gan, Hualei; Wei, Yu; Wang, Qifeng; Wang, Beihe; Wu, Junlong; Song, Shaoli; Wang, Feng; Liu, Chang; Ye, Dingwei; Zhu, Yao

Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy

CHAMPION 研究方案:一项前瞻性研究,旨在评估在接受阿帕鲁胺联合雄激素剥夺疗法全身治疗期间出现寡转移灶的初诊转移性激素敏感性前列腺癌患者的最大程度细胞减灭疗法。

Wang, Beihe; Pan, Jian; Zhang, Tingwei; Ni, Xudong; Wei, Yu; Li, Xiaomeng; Fang, Bangwei; Hu, Xiaoxin; Gan, Hualei; Wu, Junlong; Wang, Hongkai; Ye, Dingwei; Zhu, Yao

Diagnostic efficacy and interobserver agreement among readers with variable experience of the Prostate Imaging for Recurrence Reporting system with whole-mount histology after androgen deprivation therapy as a reference

以雄激素剥夺治疗后全切片组织学检查为参考,评估前列腺复发影像报告系统(PIRR)的诊断效能和不同经验水平的阅片者之间的一致性

Chen, Zhangzhe; Zhou, Bingni; Liu, Wei; Gan, Hualei; Chen, Ruchuan; Yang, Lirui; Zhou, Liangping; Liu, Xiaohang